Antifungal activity of voriconazole alone and in two-drug combination with amphotericin B in a guinea pig pulmonary aspergillosis model  by Chandrasekar, P.H. et al.
Abstracts of the 12th ISIIH 2s.51 
fungi, yet less toxic than amphotericin B. In this study, 
the effects of combining voriconazole (VOR) with 
amphotericin B (AM), Abelcet (AB), 5fluorocytosine 
(5FC), fluconazole (FLU), FK463, and MK0991 were 
investigated. 
Methods: The checkerboard combination test method 
was used to determine the synergistic, additive, in- 
different, or antagonistic interactions effect on minimum 
inhibitory concentration (MIC) values. Two antifungal 
agents are serially diluted in a desired medium to pro- 
duce 11 concentrations of the drugs under investigation. 
The range is chosen to include achievable serum levels 
of the drugs. The two antifungals are then combined into 
wells of a microtiter plate so that the concentration of 
one drug increases as that of the other also increases. 
Two rows consisting of serial dilutions of each individual 
drug are included for comparison. Yeast isolates tested 
include 3 strains each of Candida albicans, Candida 
glabrata, Candida krusei, Candida parapsibsis, Candida 
tropicalis, and Cryptococcus neoformans. Both fluco- 
nazole-susceptible and resistant strains were included. 
Results: All of the isolates tested were susceptible to 
VOR, AB, and AM. All Candida species were suscep- 
tible to MK and FK, while all Cryptococcus strains were 
resistant to these two antifungals. Susceptibility to 5-FC 
and FLU varied. Our data shows that VOR/MK 
combinations were 33% additive and 67% indifferent. 
VOR/FK combinations were 11% synergistic, 11% 
additive, and 78% indifferent. VOR/FLU combinations 
were 39% additive and 61% indifferent. VORAB com- 
binations were 22% additive and 72% indifferent.VOR/ 
AM combinations were 22% additive and 78% in- 
different. Finally, VOR/S-FC combinations were 11% 
additive and 89% indifferent. Importantly, no antag- 
onism was noted. 
Conclusion: Overall, 25.9% of all VOR combinations 
against these yeast isolates were either additive or 
synergistic, while 74.1% were indifferent, indicating 
minimal lowering of the individual MIC’s. Interactions 
were strain specific, suggesting that it is necessary to test 
combinations with each isolate. This study points to 
the need for expanded combination testing of VOR. 
Correlation with clinical outcome remains to be deter- 
mined. 
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Previous in vitro studies had shown that voriconazole 
(VCZ) in two-drug combination with conventional and 
lipid formulations of amphotericin B (AMB) produced 
indifferent interaction against Aspergillus fumigatus. TO 
confirm our in vitro finding in an animal model, we 
investigated the susceptibility of A. fumigatus 73355 
(ATCC 208996) highly susceptible to VCZ (MIC 0.25 
t.J,g/mL) and AMB (MIC 0.5 ug/mL), to two-drug com- 
bination of AMB with VCZ using a guinea pig 
pulmonary aspergillosis model. Six-to-eight week old 
guinea pigs (350+50 gram) were made neutropenic by 
three successive injections of cyclophosphamide (100 
mg/kg) on day -3, -1 and 1 where day 0 was the day of 
infection. The immunosuppressed animals (14 animals/ 
group) were challenged with 1~10~ conidia/guinea pig 
by intratracheal injection. Antifungal treatment was 
initiated on day 0 (AMB 1 mg/kg/day (i.p.), VCZ 10 
mg/kg/b.i.d. (p.0.) and AMB 1 mg/kg/day + VCZ 10 
mg/kg/b.i.d.) and continued for 7 days. The effectiveness 
of the antifungal treatments with VCZ or AMB or in 
two-drug combination was evaluated by the survival and 
the fungal burden in the lungs of infected animals. The 
mean survival of animals infected but not treated 
(controls) was 3.7225 days whereas those of the AMB, 
VCZ and AMB+VCZ treated groups were 5.3k1.9, 
5.522.1 and 5.6 +1.7 days, respectively. The fungal 
burden in the lungs of infected animals treated with 
antifungal drugs was significantly lower than that 
obtained for the untreated (109733?33877 CFU/lungs) 
group. The fungal burden of the VCZ-treated (985 ?306 
CFU/lung) group was significantly lower than that 
obtained for the AMB-treated (81912 1800 CFU/lung) 
group whereas no significant difference in the fungal 
burden was obtained for the groups treated with VCZ 
alone (985+306 CFU/lung) and VCZ+AMB (8135298 
CFU/lung). We found no antagonism between VCZ and 
AMB. The results obtained in the guinea pig pulmonary 
aspergillosis model showed good agreement with our 
previous in vitro results suggesting indifferent interaction 
of VCZ in combination with AMB against A. fumigatus. 
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Rhinocerebral zygomycosis (RCZ) or mucormycosis is a 
rare, invasive, rapidly progressive opportunistic infection 
caused by ubiquitous fungi of the order mucorales. It 
usually occurs in diabetics or immunocompromised 
patients. Disease is characterized by vascular invasion, 
thrombosis, and tissue necrosis. 
The emergency physician will typically see patients 
with RCZ in its earliest stages masquerading as a variety 
of other less serious diseases. The key markers like 
necrotic patch on hard palate, nasal septum or turbinate, 
marked facial pain, and cellulites with marked eye and 
neurological signs may present late in disease. 
